Deerfield Management Company, L.P. (Series C) Infla Rx N.V. Transaction History

Deerfield Management Company, L.P. (Series C)

$4.76 Billion
Q2 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 14, 2018	SELL	$27.33 - $41.46 $2.42 Million - $3.67 Million	-88,500 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$20.21 - $32.0 $1.75 Million - $2.77 Million	-86,500 Reduced 49.43%	88,500 $2.55 Million
Q4 2017 Feb 14, 2018	BUY	$14.55 - $23.99 $2.55 Million - $4.2 Million	175,000	175,000 $3.67 Million

Others Institutions Holding IFRX

# of Institutions

Shares Held

13.2M

Call Options Held

5.2K

Put Options Held

Suvretta Capital Management, LLC New York, NY

5.73M
Shares

$7.91 Million
0.42% of portfolio
683 Capital Management, LLC New York, NY

2.07M
Shares

$2.86 Million
0.33% of portfolio
Eversept Partners, LP New York, NY

1.57M
Shares

$2.16 Million
0.21% of portfolio
Morgan Stanley New York, NY

828K
Shares

$1.14 Million
0.0% of portfolio
Ubs Oconnor LLC Chicago, IL

722K
Shares

$996,039
0.07% of portfolio

View Full List

About InflaRx N.V.

Ticker IFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,203,800
Market Cap $61M
Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...

More about IFRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account